These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 19464926

  • 1. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP, Perianayagam MC, Jaber BL.
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M.
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
    Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A.
    Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endotoxin-binding affinity of sevelamer hydrochloride.
    Perianayagam MC, Jaber BL.
    Am J Nephrol; 2008 Mar; 28(5):802-7. PubMed ID: 18506105
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM, Reiner D, Kern M, Burke S.
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [Abstract] [Full Text] [Related]

  • 10. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
    Lee CT, Tsai YC, Ng HY, Su Y, Lee WC, Lee LC, Chiou TT, Liao SC, Hsu KT.
    J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients.
    Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ.
    Clin Nephrol; 2000 Oct; 54(4):334-41. PubMed ID: 11076110
    [Abstract] [Full Text] [Related]

  • 16. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.
    Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Cazaña-Pérez V, García-Pérez J.
    Clin J Am Soc Nephrol; 2011 Sep; 6(9):2272-9. PubMed ID: 21784820
    [Abstract] [Full Text] [Related]

  • 17. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN, Dialysis Clinical Outcomes Revisited Investigators.
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [Abstract] [Full Text] [Related]

  • 18. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do.
    Pagé D, Knoll G.
    Adv Perit Dial; 2005 Jan; 21():185-7. PubMed ID: 16686315
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.